Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice

BACKGROUND: The efficacy of temozolomide (TMZ) chemotherapy for treating newly diagnosed glioblastoma (GBM), a primary brain tumor with short survival, was demonstrated in a clinical trial in 2005, and since then, the standard-of-care for newly diagnosed GBM has been maximal safe surgery followed by...

Descripción completa

Detalles Bibliográficos
Autores principales: Carter, Tonia C., Medina-Flores, Rafael, Lawler, Benjamin E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330814/
https://www.ncbi.nlm.nih.gov/pubmed/30687753
http://dx.doi.org/10.1155/2018/6204676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330814/
https://www.ncbi.nlm.nih.gov/pubmed/30687753
http://dx.doi.org/10.1155/2018/6204676

Ejemplares similares